SAN DIEGO and STOCKHOLM, June
4 /PRNewswire/ — Amgen executive Alan Raffensperger has been appointed the
new Chief Executive Officer of BeneChill, a privately held medical
device company launching its first product, a novel cooling device
for use by emergency response teams in the field, later this year
in Europe. With more than 25
years of experience in the pharmaceutical, biotechnology, medical
device and diagnostic industries, Mr. Raffensperger joins BeneChill
from his post as Executive Director and Franchise Head of
Nephrology for Amgen, a global biopharmaceutical company. He
joined Amgen in 2005 as General Manager of the Nordic and Baltic
Region, overseeing operations in eight countries from his Sweden base.
(Photo: http://photos.prnewswire.com/prnh/20100604/LA15970)
(Photo: http://www.newscom.com/cgi-bin/prnh/20100604/LA15970)
“As we prepare to launch our lead RhinoChill™ product in
Europe, it was critical that we
recruit a seasoned, well-rounded CEO with big pharma experience and
the sensitivity to a smaller company,” said Denise Barbut, M.D., Executive Chair and
founder of BeneChill. “Ala
‘/>”/>
